These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 30290167

  • 1. Inducible SHP-2 activation confers resistance to imatinib in drug-tolerant chronic myeloid leukemia cells.
    Li X, Pang J, Xue W, Wang Y, Tian T, Elgehama A, Wu X, Wu X, Sun Y, Qiu H, Shen Y, Xu Q.
    Toxicol Appl Pharmacol; 2018 Dec 01; 360():249-256. PubMed ID: 30290167
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
    Salizzato V, Borgo C, Cesaro L, Pinna LA, Donella-Deana A.
    Oncotarget; 2016 Apr 05; 7(14):18204-18. PubMed ID: 26919095
    [Abstract] [Full Text] [Related]

  • 3. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
    Wöhrle FU, Halbach S, Aumann K, Schwemmers S, Braun S, Auberger P, Schramek D, Penninger JM, Laßmann S, Werner M, Waller CF, Pahl HL, Zeiser R, Daly RJ, Brummer T.
    Leukemia; 2013 Jan 05; 27(1):118-29. PubMed ID: 22858987
    [Abstract] [Full Text] [Related]

  • 4. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
    Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, Müller-Brüsselbach S, Ottmann OG, Duyster J, Hochhaus A, Neubauer A.
    Leukemia; 2005 Oct 05; 19(10):1774-82. PubMed ID: 16136169
    [Abstract] [Full Text] [Related]

  • 5. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X, Zhao H, Li Y, Fan J, Sun Y, Wang S, Wang Z, Song P, Ju D.
    Autophagy; 2015 Oct 05; 11(2):355-72. PubMed ID: 25701353
    [Abstract] [Full Text] [Related]

  • 6. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway.
    Huang R, Liu H, Chen Y, He Y, Kang Q, Tu S, He Y, Zhou X, Wang L, Yang J, Wu A, Li Y.
    Oncol Rep; 2018 Jan 05; 39(1):119-128. PubMed ID: 29192326
    [Abstract] [Full Text] [Related]

  • 7. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
    Lee J, Shen P, Zhang G, Wu X, Zhang X.
    Biomed Pharmacother; 2013 Mar 05; 67(2):157-63. PubMed ID: 23201011
    [Abstract] [Full Text] [Related]

  • 8. Distinct Dasatinib-Induced Mechanisms of Apoptotic Response and Exosome Release in Imatinib-Resistant Human Chronic Myeloid Leukemia Cells.
    Liu J, Zhang Y, Liu A, Wang J, Li L, Chen X, Gao X, Xue Y, Zhang X, Liu Y.
    Int J Mol Sci; 2016 Apr 08; 17(4):531. PubMed ID: 27070592
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
    Xin P, Li C, Zheng Y, Peng Q, Xiao H, Huang Y, Zhu X.
    Drug Des Devel Ther; 2017 Apr 08; 11():1115-1126. PubMed ID: 28435223
    [Abstract] [Full Text] [Related]

  • 10. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
    Hekmatshoar Y, Ozkan T, Altinok Gunes B, Bozkurt S, Karadag A, Karabay AZ, Sunguroglu A.
    Cell Mol Biol (Noisy-le-grand); 2018 May 15; 64(6):23-30. PubMed ID: 29808796
    [Abstract] [Full Text] [Related]

  • 11. Cryptotanshinone acts synergistically with imatinib to induce apoptosis of human chronic myeloid leukemia cells.
    Ge Y, Yang B, Xu X, Dai Q, Chen Z, Cheng R.
    Leuk Lymphoma; 2015 Mar 15; 56(3):730-8. PubMed ID: 24884318
    [Abstract] [Full Text] [Related]

  • 12. The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells.
    Wang H, Li Q, Tang S, Li M, Feng A, Qin L, Liu Z, Wang X.
    Hematology; 2017 May 15; 22(4):208-216. PubMed ID: 27875938
    [Abstract] [Full Text] [Related]

  • 13. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
    Tsubaki M.
    Yakugaku Zasshi; 2018 May 15; 138(12):1461-1466. PubMed ID: 30504658
    [Abstract] [Full Text] [Related]

  • 14. Propofol enhances BCR-ABL TKIs' inhibitory effects in chronic myeloid leukemia through Akt/mTOR suppression.
    Tan Z, Peng A, Xu J, Ouyang M.
    BMC Anesthesiol; 2017 Sep 29; 17(1):132. PubMed ID: 28962554
    [Abstract] [Full Text] [Related]

  • 15. Blockade of the interaction between Bcr-Abl and PTB1B by small molecule SBF-1 to overcome imatinib-resistance of chronic myeloid leukemia cells.
    Elgehama A, Chen W, Pang J, Mi S, Li J, Guo W, Wang X, Gao J, Yu B, Shen Y, Xu Q.
    Cancer Lett; 2016 Mar 01; 372(1):82-8. PubMed ID: 26721204
    [Abstract] [Full Text] [Related]

  • 16. Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
    Bandyopadhyay S, Li J, Traer E, Tyner JW, Zhou A, Oh ST, Cheng JX.
    PLoS One; 2017 Mar 01; 12(7):e0179558. PubMed ID: 28719608
    [Abstract] [Full Text] [Related]

  • 17. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
    Guo Y, Shan Q, Gong Y, Lin J, Yang X, Zhou R.
    Cancer Biol Ther; 2012 Nov 01; 13(13):1244-54. PubMed ID: 22895079
    [Abstract] [Full Text] [Related]

  • 18. Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cells.
    He W, Ye X, Huang X, Lel W, You L, Wang L, Chen X, Qian W.
    Int J Oncol; 2016 Apr 01; 48(4):1710-20. PubMed ID: 26892093
    [Abstract] [Full Text] [Related]

  • 19. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
    Yandim MK, Ceylan C, Elmas E, Baran Y.
    Tumour Biol; 2016 Feb 01; 37(2):2365-78. PubMed ID: 26373734
    [Abstract] [Full Text] [Related]

  • 20. A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
    Wagle M, Eiring AM, Wongchenko M, Lu S, Guan Y, Wang Y, Lackner M, Amler L, Hampton G, Deininger MW, O'Hare T, Yan Y.
    Leukemia; 2016 Jul 01; 30(7):1493-501. PubMed ID: 27044711
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.